Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GRK2 | P25098 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 3/20 | 0.32 |
| ▸ | CASP2 | P42575 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25682074 | 0.92 | DNM1 (0.35) | DNM1EPHX2FAAHCASP2NAAA | |
| SCHEMBL19681645 | 0.90 | FAAH (0.35) | DNM1MEN1LMNAPOLBGRK2 | |
| SCHEMBL19681644 | 0.86 | MEN1 (0.32) | DNM1MEN1LMNAPOLBGRK2 | |
| SCHEMBL25681831 | 0.81 | FAAH (0.36) | DNM1L3MBTL1EPHX2FAAHCASP2 | |
| SCHEMBL15056475 | 0.78 | MEN1 (0.49) | DNM1MEN1LMNAPOLBGRK2 | |
| SCHEMBL15057131 | 0.78 | MEN1 (0.49) | DNM1MEN1LMNAPOLBGRK2 | |
| SCHEMBL24787485 | 0.78 | DNM1 (0.33) | DNM1EPHX2FAAHCASP2NAAA | |
| SCHEMBL25681904 | 0.77 | TLR2 (0.40) | DNM1MEN1LMNAKMT2A | |
| SCHEMBL24787484 | 0.77 | TLR2 (0.40) | DNM1MEN1LMNAKMT2A | |
| SCHEMBL25681951 | 0.77 | DNM1 (0.42) | DNM1EPHX2FAAHCASP2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542229-B2 | Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2022261185-A1 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | RECODE THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20200140378-A1 | CATIONIC SULFONAMIDE AMINO LIPIDS AND AMPHIPHILIC ZWITTERIONIC AMINO LIPIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542229-B2 | Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids | ABHD16A, AARS1, CFTR | DNM1 700/4885MEN1 2129/4885LMNA 2073/4885 |
| US-20200140378-A1 | CATIONIC SULFONAMIDE AMINO LIPIDS AND AMPHIPHILIC ZWITTERIONIC AMINO LIPIDS | ABHD16A, AARS1, CFTR | DNM1 700/4885MEN1 2129/4885LMNA 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.